

TRACEIII Trial

ORIGINAL ARTICLE

Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy


Design: phase 3, multicenter, blinded-outcome, randomized controlled trial.

Inclusion Criteria:	Salvageable Tissue Criteria:
<ul style="list-style-type: none"> - Ischemic Stroke with LVO, who didn't go for thrombectomy - Time: 4.5-24h from LKW - mRS: 0-1 - NIHSS: 6-25 - LVO: ICA, M1, M2 - Evidence of Salvageable tissue >> 	<ul style="list-style-type: none"> - Core < 70ml - Penumbra > 15 ml - Penumbra/Core ratio: 1.8

Baseline Characteristics			
	TNK		No Thrombolysis
NIHSS – Median	11		10
Onset	Known	54%	59%
	Wake-Up	38.3%	33.3%
Core - Median	16.4		14.9
Penumbra – Median	119		123

Treatment Arms: 262 patients were assigned to TNK arm and 252 assigned to the standard medical treatment

Trace III Outcomes		
	TNK	No Thrombolysis
90d mRS 0-1	33%	24.2%
90d mRS 0-2	43.6%	33.3%
Major improvement in 72h	16%	6%
sICH	3%	0.8%
Death within 90 days	13%	13%
Any serious adverse events	20.1%	17.1%



Critique: This study applies mainly to patients in remote areas with no access to thrombectomy. In patients with LVO who can receive thrombectomy, TIMELESS trial showed no benefit from thrombolysis.

Bottom Line: In patients with LVO who didn't go for thrombectomy (mainly due to lack of access), treatment with TNK in an extended window of 4.5-24h was associated with less disability